RxDoctor Payments DataLook up a doctor →

Shane Watts, APRN

Psychiatric/Mental Health · Louisville, KYNPI 1285385005

Payments from drug & device makers

$12,675in general payments, 2019–2025

Across 857 payments — averaging $14.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Bausch Health US, LLC$1K
  • Alkermes, Inc.$1K
  • Lundbeck LLC$927
  • Otsuka America Pharmaceutical, Inc.$870
  • plus $5K from 18 others

What the payments were for

  • Food & beverage$12,614100%
  • Education$610%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,675 in reported general payments places this provider in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.

See all psychiatric/mental health providers in Kentucky

Medicare billing

Part B allowed, 2024
$9,234
Medicare patients
37
Services billed
99

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl28$40,169
RexultiBrexpiprazole13$20,391
TrintellixVortioxetine Hydrobromide12$7,685
Quetiapine Fumarate81$3,252
Aripiprazole21$2,779
Prazosin Hcl35$1,569
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine55$1,567
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine37$1,129
Clonazepam115$1,049
Trazodone Hcl95$936
Bupropion XlBupropion Hcl60$855
Mirtazapine81$735
Alprazolam ErAlprazolam23$545
Amitriptyline Hcl15$535
Fluoxetine Hcl83$532

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,935$40,16928 claims
Otsuka America Pharmaceutical, Inc.Rexulti$870$20,39113 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$555$7,68512 claims
Almatica Pharma LLCSertraline Hcl$99$12647 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.

Other psychiatric/mental health in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →